The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

Biodegradable cross-linked particles, as well as related compositions and methods, are disclosed.

A pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core including crystalline L-menthol dissolved in a terpene-based essential oil. A proteinaceous coating of a continuous film of proteinaceous material is over the core.

Biodegradable cross-linked particles, as well as related compositions and methods, are disclosed.

The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases.

A storage stable L-menthol composition includes a tablet, caplet, capsule, or sachet dosage form. The dosage form has (a) a plurality of individual cores containing an L-menthol source and at least one pharmaceutical excipient and (b) a proteinaceous coating of a continuous film of proteinaceous material over the individual cores forming a plurality of proteinaceous coated individual cores. The film is effective to substantially prevent L-menthol in the L-menthol source from leaving the individual cores when stored at a temperature of 40 degrees C. and 75% relative humidity for at least 1 day. The dosage form contains an effective amount of the L-menthol source for treating a gastrointestinal disorder.